Ghent University Academic Bibliography

Your filters: cql: author=" Yoon, Sung-Soo" or (type any "bookEditor issueEditor" and editor=" Yoon, Sung-Soo")

Add to list
- Journal Article
- A2
- open access
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial

Paul G. Richardson, Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner (UGent) , Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung-Soo Yoon, et al.

(2023) EJHAEM. 4(4). p.995-1005
Add to list
- Conference Paper
- C3
Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

Simon Harrison, Caroline Hasselbalch Riley, Salomon Manier, Sung-Soo Yoon, Antonio Pinto, Titouan Cazaubiel, Anna Guidetti, Rakesh Popat, Cyrille Touzeau, Enrique Ocio, et al.

(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 2). p.S3-S3
Add to list
Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses

Simon Harrison, Caroline Hasselbalch Riley, Salomon Manier, Sung-Soo Yoon, Antonio Pinto, Titouan Cazaubiel, Anna Guidetti, Rakesh Popat, Cyrille Touzeau, Enrique Ocio, et al.

(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 2). p.S3-S4
Add to list
- Miscellaneous
- open access
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing (vol 52, pg 331, 2020)

Isidro Cortes-Ciriano, Jake June-Koo Lee, Ruibin Xi, Dhawal Jain, Youngsook L. Jung, Lixing Yang, Dmitry Gordenin, Leszek J. Klimczak, Cheng-Zhong Zhang, David S. Pellman, et al.

(2023) NATURE GENETICS. 55.
Add to list
- Conference Paper
- C3
RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM) : updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study

Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J. Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.397-399
Add to list
- Conference Paper
- C3
Intravenous and subcutaneous administration of RG6234, a novel GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients with relapsed/refractory multiple myeloma (RRMM) : biomarker results from a phase I study

Iryna Dekhtiarenko, Iva Lelios, Jan Attig, Nassim Sleiman, Domenico Lazzaro, Emilie Schindler, Jan Eckmann, Pablo Umana, Wolfgang Jacob, Meike Schneider, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.10137-10139

Academic Bibliography

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial

Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses

Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing (vol 52, pg 331, 2020)

RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM) : updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study

Intravenous and subcutaneous administration of RG6234, a novel GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients with relapsed/refractory multiple myeloma (RRMM) : biomarker results from a phase I study

Contents

Support

Contact